{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:44:11Z","timestamp":1792687451363,"version":"4.5.0"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["grant FWO G.0399.14N"],"award-info":[{"award-number":["grant FWO G.0399.14N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Belgian Foundation against Cancer","doi-asserted-by":"publisher","award":["2012-193"],"award-info":[{"award-number":["2012-193"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.pharmthera.2015.11.008","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T17:54:49Z","timestamp":1448301289000},"page":"24-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":203,"special_numbering":"C","title":["Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials"],"prefix":"10.1016","volume":"158","author":[{"given":"Heleen H.","family":"Van Acker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Anguille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Willemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien L.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viggo F.","family":"Van Tendeloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.11.008_bb0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0010","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10549-014-2906-x","article-title":"A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events","volume":"144","author":"Addison","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/bjc.2012.210","article-title":"Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II\/III breast cancer","volume":"107","author":"Aft","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0035","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00002018-200326090-00005","article-title":"Extended safety profile of oral clodronate after long-term use in primary breast cancer patients","volume":"26","author":"Atula","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma","volume":"24","author":"Aviles","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0045","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.3747\/co.20.1055","article-title":"Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation","volume":"20","author":"Aviles","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0050","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2407-10-462","article-title":"Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone","volume":"10","author":"Balke","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0055","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1471-2407-13-480","article-title":"Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial","volume":"13","author":"Banys","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0065","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0070","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2407-12-35","article-title":"Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors","volume":"12","author":"Bonde","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.12090","article-title":"Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside","volume":"160","author":"Braza","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0085","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdu102","article-title":"Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II\/III breast cancer: the NEOZOTAC trial (BOOG 2010\u201301)","volume":"25","author":"Charehbili","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0090","first-page":"I31","article-title":"Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma","volume":"8","author":"Ciepluch","year":"2002","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/187152012799014977","article-title":"Potential anticancer properties of bisphosphonates: insights from preclinical studies","volume":"12","author":"Clezardin","year":"2012","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0110","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0100","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0105","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"Coleman","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0115","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0120","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2013.10.004","article-title":"Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy","volume":"58","author":"Cornelis","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.21104","article-title":"Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect","volume":"104","author":"Corso","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0135","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1582-4934.2009.00926.x","article-title":"Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway","volume":"14","author":"Coscia","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0140","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10147-012-0414-8","article-title":"Treatment of bone metastases before the onset of pain","volume":"18","author":"Costa","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1464-4096.2004.04831.x","article-title":"Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation","volume":"94","author":"Coxon","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0145","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","article-title":"Recent advances in understanding the mechanism of action of bisphosphonates","volume":"6","author":"Coxon","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0155","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D'Arena","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0160","doi-asserted-by":"crossref","first-page":"637976","DOI":"10.1155\/2013\/637976","article-title":"Bisphosphonates and cancer: what opportunities from nanotechnology?","volume":"2013","author":"De Rosa","year":"2013","journal-title":"J Drug Deliv"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0165","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0170","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbagen.2012.07.013","article-title":"Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid","volume":"1820","author":"Dedes","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0175","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ctrv.2014.04.003","article-title":"Recent advances in bone-targeted therapies of metastatic prostate cancer","volume":"40","author":"Deng","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0180","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","volume":"15","author":"Denham","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0185","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S1470-2045(12)70423-0","article-title":"Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial","volume":"13","author":"Denham","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0190","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2012.09.018","article-title":"Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer","volume":"105","author":"Denham","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0195","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0200","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0205","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"10001","key":"10.1016\/j.pharmthera.2015.11.008_bb0210","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2014.05.008","article-title":"Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"352","author":"Fan","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2407-14-66","article-title":"FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients","volume":"14","author":"Fasching","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0225","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-014-2840-y","article-title":"Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the \u201cbiological window therapy\u201d","volume":"144","author":"Foroni","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10147-010-0179-x","article-title":"Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer","volume":"16","author":"Francini","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0240","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.ajpath.2011.05.034","article-title":"Macrophage infiltration predicts a poor prognosis for human ewing sarcoma","volume":"179","author":"Fujiwara","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0245","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1399-0012.2011.01527.x","article-title":"Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation","volume":"26","author":"Ganguly","year":"2012","journal-title":"Clin Transpl"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0250","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30mg versus 90mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0255","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0260","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0265","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0270","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0280","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0285","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.ejca.2013.03.018","article-title":"Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group","volume":"49","author":"Goldsby","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0290","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/1078-0432.CCR-14-2279","article-title":"Rac1\/Pak1\/p38\/MMP-2 axis regulates angiogenesis in ovarian cancer","volume":"21","author":"Gonzalez-Villasana","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0295","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3109\/07357907.2010.512598","article-title":"Anticancer properties of zoledronic acid","volume":"28","author":"Green","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0300","first-page":"688","article-title":"Sensing of pyrophosphate metabolites by Vgamma9Vdelta2 T cells","volume":"5","author":"Gu","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0305","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0310","doi-asserted-by":"crossref","first-page":"948098","DOI":"10.1155\/2012\/948098","article-title":"Macrophages in tumor microenvironments and the progression of tumors","volume":"2012","author":"Hao","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0315","doi-asserted-by":"crossref","first-page":"480","DOI":"10.6004\/jnccn.2015.0061","article-title":"Routine use of zoledronic acid in early-stage breast cancer","volume":"13","author":"Harnden","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0320","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/pros.22590","article-title":"Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer","volume":"73","author":"Hashimoto","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0325","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0330","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2354.2007.00808.x","article-title":"Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer","volume":"16","author":"Heras","year":"2007","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0335","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2354.2008.00980.x","article-title":"Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer","volume":"18","author":"Heras","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0340","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0345","first-page":"3623","article-title":"Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study","volume":"31","author":"Hoffmann","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0350","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2014.3634","article-title":"Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid","volume":"174","author":"Hue","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0355","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1582-4934.2012.01527.x","article-title":"Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells","volume":"16","author":"Insalaco","year":"2012","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0360","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fimmu.2014.00514","article-title":"From monocytes to M1\/M2 macrophages: phenotypical vs functional differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0365","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel Era\u201d: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0370","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2159-8290.CD-14-0621","article-title":"Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer","volume":"5","author":"Junankar","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0375","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1442-2042.2011.02914.x","article-title":"Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade","volume":"19","author":"Kamiya","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0380","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000100840","article-title":"Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels","volume":"78","author":"Kawashima","year":"2007","journal-title":"Urol Int"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0385","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","article-title":"Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates","volume":"86","author":"Kimmel","year":"2007","journal-title":"J Dent Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.icb.7100113","article-title":"sIL-6R: more than an agonist?","volume":"86","author":"Knupfer","year":"2008","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0395","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/pbc.22428","article-title":"Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL)","volume":"54","author":"Kotecha","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0400","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0360-3016(03)00525-X","volume":"57","author":"Kouloulias","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0405","first-page":"w13979","article-title":"Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature","volume":"144","author":"Kreutle","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0410","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"Kristensen","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0415","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","article-title":"Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I\/II trial","volume":"35","author":"Kunzmann","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0420","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0425","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood-2013-04-498139","article-title":"The impact of response on bone-directed therapy in patients with multiple myeloma","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0430","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/pbc.24313","article-title":"Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia","volume":"60","author":"Leblicq","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0440","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00520-013-2017-y","article-title":"Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies","volume":"22","author":"Lee","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0435","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1158\/0008-5472.CAN-12-4563","article-title":"BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages","volume":"73","author":"Lee","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0445","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-004-3722-5","article-title":"Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer","volume":"90","author":"Leppa","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0450","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0455","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ncb3041","article-title":"A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages","volume":"16","author":"Lu","year":"2014","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0460","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0470","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0465","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ejca.2009.12.003","article-title":"Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer","volume":"46","author":"McCloskey","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0475","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/0008-5472.CAN-09-2995","article-title":"Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy","volume":"70","author":"Meng","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0480","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0485","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0490","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ejca.2012.05.014","article-title":"Randomised phase II\/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)","volume":"48","author":"Meulenbeld","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0495","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.25744","article-title":"Addition of pamidronate to chemotherapy for the treatment of osteosarcoma","volume":"117","author":"Meyers","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0500","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188.pub3","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","volume":"5","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0505","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2010.12.024","article-title":"The kidney and bisphosphonates","volume":"49","author":"Miller","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0510","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.2058","article-title":"Renal safety in patients treated with bisphosphonates for osteoporosis: a review","volume":"28","author":"Miller","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0515","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bone.2009.08.010","article-title":"The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro","volume":"45","author":"Mitrofan","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0520","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bcp.2006.09.031","article-title":"Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro","volume":"73","author":"Moreau","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0525","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0530","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0535","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0540","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejca.2009.10.019","article-title":"Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma","volume":"46","author":"Moschetta","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0545","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/cas.12448","article-title":"Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group","volume":"105","author":"Murakami","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0550","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0555","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0560","unstructured":"National Comprehensive Cancer Network (NCCN), 2015. Breast Cancer (Version 3.2015). In (Vol. 2015); 2015."},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0570","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients","volume":"70","author":"Odri","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0565","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1471-2407-14-169","article-title":"Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration","volume":"14","author":"Odri","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0575","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bone.2014.03.005","article-title":"Pleiotropic effects of bisphosphonates on osteosarcoma","volume":"63","author":"Ohba","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0580","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/jbmr.2182","article-title":"Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL","volume":"29","author":"Ohba","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0585","first-page":"4415","article-title":"Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naive prostate cancer in a multicenter clinical trial","volume":"34","author":"Okegawa","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0590","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/jor.22714","article-title":"Osteoclast inhibition impairs chondrosarcoma growth and bone destruction","volume":"32","author":"Otero","year":"2014","journal-title":"J Orthop Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0595","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","article-title":"Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo","volume":"20","author":"Ottewell","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0600","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0605","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2141.2007.06578.x","article-title":"Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I\/II study in patients in complete haematological remission","volume":"137","author":"Pavlu","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12551","article-title":"Questioning the association between bisphosphonates and atypical femoral fractures","volume":"1335","author":"Pazianas","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0615","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0620","first-page":"1807","article-title":"Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer","volume":"30","author":"Rack","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0625","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jconrel.2011.11.020","article-title":"Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel","volume":"158","author":"Ramanlal Chaudhari","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0630","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bone.2010.03.006","article-title":"A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites","volume":"47","author":"Reinholz","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0635","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1479-5876-9-177","article-title":"Tumour macrophages as potential targets of bisphosphonates","volume":"9","author":"Rogers","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0645","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0640","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0650","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/pbc.22821","article-title":"A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent\/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study","volume":"57","author":"Russell","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0655","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0660","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0665","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0670","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2012.05.007","article-title":"Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid","volume":"65","author":"Saad","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0675","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101260","article-title":"Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells","volume":"9","author":"Sabatino","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0685","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12032-007-9004-4","article-title":"Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma","volume":"25","author":"Saitoh","year":"2008","journal-title":"Med Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0690","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","volume":"56","author":"Sanfilippo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0695","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ncponc0520","article-title":"Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates","volume":"3","author":"Santini","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0700","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0705","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0710","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/annonc\/mds128","article-title":"Zoledronic acid in patients with stage IIIA\/B NSCLC: results of a randomized, phase III study","volume":"23","author":"Scagliotti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0715","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1535-7163.MCT-07-0311","article-title":"Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma","volume":"6","author":"Scavelli","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0720","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0725","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.4161\/15384047.2014.955989","article-title":"Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique","volume":"15","author":"Schiraldi","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0730","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMe1003064","article-title":"Evolving data about subtrochanteric fractures and bisphosphonates","volume":"362","author":"Shane","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074402","article-title":"Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey","volume":"8","author":"Silvestris","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0740","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM198002073020602","article-title":"Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma","volume":"302","author":"Siris","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0745","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0750","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1093\/annonc\/mdr612","article-title":"Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients","volume":"23","author":"Solomayer","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0755","doi-asserted-by":"crossref","first-page":"17995","DOI":"10.1073\/pnas.1421422111","article-title":"Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer","volume":"111","author":"Stachnik","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0760","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00264-010-1130-5","article-title":"Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78","volume":"35","author":"Streitbuerger","year":"2011","journal-title":"Int Orthop"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0765","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2010.09.035","article-title":"Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase","volume":"48","author":"Stresing","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0770","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12967-014-0310-2","article-title":"Effects of zoledronic acid and the association between its efficacy and gammadeltaT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol","volume":"12","author":"Sumi","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0775","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10555-013-9480-2","article-title":"Bone-targeting agents in prostate cancer","volume":"33","author":"Suzman","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0780","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3892\/or.2011.1152","article-title":"Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines","volume":"25","author":"Tamura","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0785","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0790","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0795","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","article-title":"Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma","volume":"70","author":"Terpos","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0800","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1016\/j.biomaterials.2012.06.026","article-title":"Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer","volume":"33","author":"Thamake","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0805","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1021\/bc100071k","article-title":"188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases","volume":"21","author":"Torres Martin de Rosales","year":"2010","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0810","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0815","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.taap.2012.01.024","article-title":"Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529\/ONO-5920-induced blockade of the Ras\/MEK\/ERK and Ras\/PI3K\/Akt pathway","volume":"259","author":"Tsubaki","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0820","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2007.01.031","article-title":"Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface","volume":"354","author":"Uchida","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0825","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10147-012-0406-8","article-title":"Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial","volume":"18","author":"Uemura","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0830","first-page":"3837","article-title":"Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid\/androgen blockade trial on prostate cancer) study","volume":"33","author":"Ueno","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0835","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1021538","article-title":"Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy","volume":"4","author":"Van Acker","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0840","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2003-03-0970","article-title":"Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels","volume":"102","author":"van de Donk","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0845","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjc.6605814","article-title":"Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma","volume":"103","author":"Veltman","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0850","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0855","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12032-013-0657-x","article-title":"Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases","volume":"30","author":"Wang","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0860","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0865","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clml.2012.11.002","article-title":"Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial","volume":"13","author":"Westin","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0870","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/187152012799014959","article-title":"The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics","volume":"12","author":"Widler","year":"2012","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0875","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-12-3235","article-title":"Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer\u2014a randomized biomarker pilot study","volume":"19","author":"Winter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0880","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0885","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/jid.2014.206","article-title":"Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo","volume":"134","author":"Wu","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0890","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/hep.26735","article-title":"Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression","volume":"59","author":"Xia","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0895","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010382","article-title":"A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin","volume":"6","author":"Xia","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0900","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jss.2008.01.031","article-title":"Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation","volume":"151","author":"Yamada","year":"2009","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0905","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","article-title":"The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials","volume":"48","author":"Yan","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0910","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0915","doi-asserted-by":"crossref","first-page":"14614","DOI":"10.1038\/srep14614","article-title":"Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer","volume":"5","author":"Ye","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0920","doi-asserted-by":"crossref","first-page":"17989","DOI":"10.1073\/pnas.1421410111","article-title":"Bisphosphonates inactivate human EGFRs to exert antitumor actions","volume":"111","author":"Yuen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0925","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0930","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10549-010-1183-6","article-title":"Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance","volume":"124","author":"Zhao","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0935","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/1471-2407-11-403","article-title":"Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving \u201cmetronomic\u201d zoledronic acid","volume":"11","author":"Zhao","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2015.11.008_bb0940","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ejca.2010.12.004","article-title":"Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases","volume":"47","author":"Zhao","year":"2011","journal-title":"Eur J Cancer"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815002211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815002211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T18:54:18Z","timestamp":1653591258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815002211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":188,"alternative-id":["S0163725815002211"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.11.008","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}